|
2.11 Etiologie - Alimentation
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.1 Dép., diag. & prono. - Prostate
|
|
|
|
|
|
The Task Force Shift on PSA: It Really IS A Big Deal [Dr. Len]
|
|
|
|
|
|
Medicine
actually has moved in a more evidence based direction. Doctors do less
surgery and radiation, fewer men have incontinence, and although their
sex lives are interrupted, the basis for that interruption may be more
understandable. And one still has the opportunity to avoid a death from
prostate cancer.
|
|
|
|
|
|
|
|
|
|
Prostate Cancer Screening Draft Recommendations [USPTF]
|
|
|
|
|
|
This
draft recommendation statement is being distributed solely for the
purpose of receiving public input. It has not been disseminated
otherwise by the USPSTF. The final recommendation statement will be
developed after careful consideration of the feedback received.
|
|
|
|
|
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
|
5. Traitements
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
Personalized tumor vaccines keep cancer in check [Science]
|
|
|
|
|
|
Pardoll
and others caution, however, that it’s not possible to know whether
neoantigen vaccines perform better than a PD-1 inhibitor alone without
doing larger studies. Other questions remain about how best to design
and deliver neoantigen vaccines. Right now the vaccines are costly and
take months to make, which may be too long for some patients with
metastatic disease.
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
Novartis advances with push on cancer and liver disease [Reuters]
|
|
|
|
|
|
The
Basel-based drugmaker's chimeric antigen receptor therapy (CAR-T)
treatment, called CTL019, was awarded the U.S. Food and Drug
Administration's breakthrough therapy designation for adults with
relapsed/refractory (r/r) diffuse large B-cell lymphoma, a common blood
cancer.
|
|
|
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
Glioblastoma Patients May Benefit from a Vaccine-Chemotherapy Combination [AACR]
|
|
|
|
|
|
The
cohort of 11 patients who received this combination therapy
demonstrated a median progression-free survival of 25.3 months and a
median overall survival of 41.1 months, and three patients remain
progression-free more than seven years after diagnosis, Batich said. By
contrast, the typical median survival for GBM patients is less than 15
months.
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.2 Pharma
|
|
|
|
|
OncoMed's lung cancer drug fails mid-stage study, shares tumble [Reuters]
|
|
|
|
|
|
The
main goal for Tarextumab, which the company is developing in
partnership with GlaxoSmithKline Plc, was to slow the progression of the
disease. The company said the tarextumab study also failed the
secondary goal of overall survival benefit. OncoMed also said on
Monday it would also discontinue enrollment in an early-stage trial
testing its drug, brontictuzumab, in combination with chemotherapy in
patients with colorectal cancer due to toxicity issues.
|
|
|
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
EMA Updates Guidance on Clinical Data Publication Policy [RAPS]
|
|
|
|
|
|
The
policy, known as Policy 0070, is part of a push towards greater
clinical trial transparency by EMA through the publication of clinical
data submitted as part of marketing authorization applications to be
published in an online database, regardless of whether the product is
ultimately authorized, rejected or withdrawn.
|
|
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
FDA Approves Pembrolizumab for Hodgkin Lymphoma [NCI]
|
|
|
|
|
|
No
pediatric patients participated in the clinical trial on which the
approval was based. In this instance, the FDA extrapolated the efficacy
in pediatric patients from the results that were observed in adults.
This is a bit unusual, said Gregory Reaman, M.D., a pediatric oncologist
and associate director for Oncology Sciences in the Office of
Hematology and Oncology Products at the FDA.
|
|
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.9 AACR
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
When I use a word . . . Translational research—a new operational model [BMJ Blogs]
|
|
|
|
|
|
This
model includes two other features of research in relation to healthcare
that earlier models neglect: (a) a bar linking basic and applied
research, implying that they form a continuum not a dichotomy, and (b)
the recognition that cost utility or cost effectiveness analyses (black
bars) are necessary in judging whether to implement a technology in
clinical practice.
|
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.11 Patients
|
|
|
|
6.12 Ethique
|
|
|
|
|
|
6.3 Associations/Fondations
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.6 Publications
|
|
|
|
The ORCID Open Letter: One Year On [ORCID]
|
|
|
|
|
|
Sixteen
organizations have gone live with requiring ORCID iDs for their authors
so far. These organizations have generally followed our best practice
guidelines, and since the open letter was published, over 250,000
articles have included ORCID iDs in their Crossref submission.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
One of Google's most embarrassing flops is turning into a real business [CNBC]
|
|
|
|
|
|
Augmedix
sells its application to 12 hospitals, including Dignity Health, Sutter
Health and TriHealth, to help doctors transcribe notes from patient
interactions. Doctors wear the glasses during consultations and transmit
video to medical scribes, who take notes. That way, the doctors are
freed up to focus on the patients.
|
|
|
|
|
|
|
6.9 Controverses
|
|
|
|
Interview with Professor Doug Altman [MiRoR]
|
|
|
|
|
|
There
is a lot of confusing literature on what people think reproducibility
is, because it has multiple meanings. The fact is that in many fields,
this is a major concern. Non-reproducible findings are in part a
consequence of selective publication and the dominance of significance
as a means of drawing inference.
|
|
|
|
|
|